Path ID: DB12233_MESH_D001172_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:C519076 | iguratimod | Drug |
| UniProt:P3535 | Prostaglandin G/H synthase 2 | Protein |
| UniProt:O00463 | TNF receptor-associated factor 5 | Protein |
| UniProt:Q14164 | Inhibitor of nuclear factor kappa-B kinase subunit epsilon | Protein |
| UniProt:O43734 | E3 ubiquitin ligase TRAF3IP2 | Protein |
| UniProt:A6MUU8 | Macrophage migration inhibitory factor | Protein |
| reactome:R-HSA-448424 | Interleukin-17 signaling | Pathway |
| reactome:R-HSA-5668541 | TNFRSF mediated non-canonical NF-kB pathway | Pathway |
| GO:0007253 | cytoplasmic sequestering of NF-kappaB | BiologicalProcess |
| GO:0006954 | inflammatory response | BiologicalProcess |
| MESH:D001172 | Rheumatoid arthritis | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Iguratimod | DECREASES ACTIVITY OF | Prostaglandin G/H Synthase 2 |
| Iguratimod | NEGATIVELY REGULATES | Macrophage Migration Inhibitory Factor |
| Macrophage Migration Inhibitory Factor | POSITIVELY REGULATES | Interleukin-17 Signaling |
| Iguratimod | NEGATIVELY REGULATES | Tnf Receptor-Associated Factor 5 |
| Tnf Receptor-Associated Factor 5 | POSITIVELY REGULATES | Interleukin-17 Signaling |
| Iguratimod | NEGATIVELY REGULATES | E3 Ubiquitin Ligase Traf3Ip2 |
| E3 Ubiquitin Ligase Traf3Ip2 | POSITIVELY REGULATES | Interleukin-17 Signaling |
| Iguratimod | NEGATIVELY REGULATES | Inhibitor Of Nuclear Factor Kappa-B Kinase Subunit Epsilon |
| Inhibitor Of Nuclear Factor Kappa-B Kinase Subunit Epsilon | POSITIVELY REGULATES | Interleukin-17 Signaling |
| Interleukin-17 Signaling | POSITIVELY REGULATES | Inflammatory Response |
| Iguratimod | POSITIVELY REGULATES | Cytoplasmic Sequestering Of Nf-Kappab |
| Cytoplasmic Sequestering Of Nf-Kappab | NEGATIVELY REGULATES | Tnfrsf Mediated Non-Canonical Nf-Kb Pathway |
| Tnfrsf Mediated Non-Canonical Nf-Kb Pathway | POSITIVELY REGULATES | Inflammatory Response |
| Prostaglandin G/H Synthase 2 | POSITIVELY REGULATES | Inflammatory Response |
| Inflammatory Response | POSITIVELY CORRELATED WITH | Rheumatoid Arthritis |
Comment: Iguratimod (IGU) is a novel synthetic small molecule disease modified anti-rheumatic drug approved only in Japan and China. The mechanism of action is broadly reported as anti-inflammatory, immunomodulatory and osteoprotective mechanism.
Reference: